A61K 39/001192
Glycoprotein 100 [gp100]
Official title: {Glycoprotein 100 [Gp100]}
A61K39/001192 (Glycoprotein 100 [gp100]) appears on 125 US grants and 274 published applications in this corpus.
Search patents in A61K- Granted patents
- 125
- Published applications
- 274
- Assignees
- 146
- Inventors
- 506
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 1 |
| 2002 | 3 | 9 |
| 2003 | 2 | 5 |
| 2004 | 0 | 12 |
| 2005 | 2 | 5 |
| 2006 | 0 | 6 |
| 2007 | 2 | 2 |
| 2008 | 1 | 8 |
| 2009 | 1 | 3 |
| 2010 | 5 | 6 |
| 2011 | 5 | 12 |
| 2012 | 2 | 12 |
| 2013 | 0 | 3 |
| 2014 | 6 | 11 |
| 2015 | 3 | 19 |
| 2016 | 8 | 28 |
| 2017 | 7 | 13 |
| 2018 | 9 | 17 |
| 2019 | 7 | 10 |
| 2020 | 7 | 17 |
| 2021 | 13 | 15 |
| 2022 | 11 | 20 |
| 2023 | 8 | 19 |
| 2024 | 6 | 6 |
| 2025 | 4 | 9 |
| 2026 | 7 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- Antiviral vaccines using spherical nucleic acids28 Jul 2026US 12,691,166 B2Northwestern University
- Immune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same21 Jul 2026US 12,685,780 B2Daiichi Sankyo Company, Limited
- T cell receptors and methods of use thereof28 Apr 2026US 12,611,450 B2University Health Network
- CpG ODN having immunoregulatory function and use thereof14 Apr 2026US 12,600,973 B2Parr Biotechnology (Hebei) Co., Ltd.
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Immune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same24 Sep 2026US 2026/0284210 A1Daiichi Sankyo Company, Limited
- Peptide linkers for modulating antigen immune response in cancer vaccines27 Aug 2026US 2026/0248899 A1Northwestern University
- Methods of treating cancer with a combination of a cancer vaccine and a taaxcd28 bispecific antigen-binding molecule11 Jun 2026US 2026/0159586 A1Regeneron Pharmaceuticals, Inc.
- Polymeric nanovaccines and uses thereof21 May 2026US 2026/0137804 A1Ramot at Tel-Aviv University Ltd.
Most cited
By later US patents
- DNA vaccine and methods for its use107US 6,472,375 B1John Wayne Cancer Institute · 2002
- Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same90US 5,891,432 AThe Immune Response Corporation · 1999
- Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof79US 9,572,874 B2CureVac AG · 2017
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011